
|Videos|July 16, 2014
Updates In CLL Treatments
Author(s)John C. Byrd, MD
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.
Advertisement
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.
Clinical Pearls:
- Patient-friendly therapies are changing the lives of patients with CLL.
- These oral therapies are active and successfully controlling the disease for an extended period of time.
- By combining new, active agents, physicians are moving closer to finding a cure for patients with CLL.
- With updates in treatment options, physicians can now start to move away from using chemotherapy to treat patients with CLL.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































